INLURIYO Trademark

Trademark Overview

On Thursday, July 14, 2022, a trademark application was filed for INLURIYO with the United States Patent and Trademark Office. The USPTO has given the INLURIYO trademark a serial number of 97503653. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Tuesday, April 21, 2026. This trademark is owned by Eli Lilly and Company. The INLURIYO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of a cancer
inluriyo

General Information

Serial Number97503653
Word MarkINLURIYO
Filing DateThursday, July 14, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateTuesday, April 21, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 6, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of a cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 4, 2022
Primary Code005
First Use Anywhere DateFriday, October 31, 2025
First Use In Commerce DateFriday, October 31, 2025

Trademark Owner History

Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
US
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
US

Trademark Events

Event DateEvent Description
Monday, July 18, 2022NEW APPLICATION ENTERED
Thursday, August 4, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 28, 2023ASSIGNED TO EXAMINER
Sunday, April 30, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 17, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 6, 2023PUBLISHED FOR OPPOSITION
Tuesday, June 6, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 1, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, January 8, 2024SOU TEAS EXTENSION RECEIVED
Monday, January 8, 2024SOU EXTENSION 1 FILED
Monday, January 8, 2024SOU EXTENSION 1 GRANTED
Wednesday, January 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 12, 2024SOU TEAS EXTENSION RECEIVED
Friday, July 12, 2024SOU EXTENSION 2 FILED
Friday, July 12, 2024SOU EXTENSION 2 GRANTED
Friday, July 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 9, 2025SOU TEAS EXTENSION RECEIVED
Thursday, January 9, 2025SOU EXTENSION 3 FILED
Thursday, January 9, 2025SOU EXTENSION 3 GRANTED
Thursday, January 9, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 10, 2025SOU TEAS EXTENSION RECEIVED
Thursday, July 10, 2025SOU EXTENSION 4 FILED
Thursday, July 10, 2025SOU EXTENSION 4 GRANTED
Friday, July 11, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 6, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, November 6, 2025USE AMENDMENT FILED
Tuesday, April 14, 2026STATEMENT OF USE PROCESSING COMPLETE
Tuesday, April 21, 2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, April 21, 2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

inluriyo pharmaceutical preparations cancer namely treatment